Phase 2Status unknownAge-related condition

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

Sponsor
Mercator MedSystems, Inc. (Industry)
Enrollment
100 planned
Conditions
Chronic Limb Ischemia
Interventions
Temsirolimus; Saline
Ages
adults, older adults
Registry
NCT02908035

Full record on ClinicalTrials.gov

From the registry

This is a prospective, multi-center, randomized, dose escalation study to document the effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).

Primary outcomes

  • Freedom from MALE-POD
  • Transverse-view vessel area loss percentage (TVAL%) of the target lesion

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Started

  5. Registered